Sharemaestro company-news research for Stryker Corporation (S1YK34), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
Company news sentiment
Latest S1YK34 news and sentiment
Stryker Corporation
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
Early balanced news score
19 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
19 current stories are mapped specifically to S1YK34.
The score uses 4 publishers rather than depending on one outlet.
What limits the score
The stories agree, but freshness-weighted evidence is only 0.157.
Confidence is 22/100, below the threshold for a firm score.
News history
Daily score and story count over 30 days
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Price and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
News subjects
What is shaping the score
Source mix
Where the evidence comes from
Recurring subjects
Subjects appearing most often
Earlier readings
How the score has changed
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 21 Sep 13:11 | 51 | -1 | 18/100 (-8) | 21 (-5) | Provisional |
| 17 Sep 23:59 | 52 | +1 | 26/100 (+4) | 26 (+2) | Provisional |
| 15 Sep 23:59 | 51 | +0 | 22/100 (-3) | 24 (+1) | Provisional |
| 14 Sep 23:59 | 51 | -1 | 25/100 (-5) | 23 (-3) | Provisional |
| 10 Sep 23:59 | 52 | -1 | 30/100 (-1) | 26 (0) | Provisional |
| 09 Sep 23:59 | 53 | +2 | 31/100 (+7) | 26 (+4) | Provisional |
| 08 Sep 23:59 | 51 | -1 | 24/100 (+5) | 22 (0) | Provisional |
| 04 Sep 23:59 | 52 | +0 | 19/100 (0) | 22 (+1) | Provisional |
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
Stryker Facing Promising Setup Next Year, Trading Upside Limited in 2026, RBC Says
Stryker (SYK) will likely see an acceleration story in 2027, with high single digit growth achievabl PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in
- Published
- 17 Sep 2026 15:14
- News subject
- Analyst action
- Why this score
- Positive financial language
- Company focus
- Shared story ยท 78%
- How it is used
- Direct company coverage
- Story strength
- Medium ยท 41/100
- 30-day weight
- 19.7% of the score ยท 3.9d old
- Duplicates
- 1 consolidated
Stryker Expands Foot & Ankle Innovation With Prophecy and smartHEX
Stryker SYK recently announced the expansion of its Foot & Ankle portfolio with the launch of Prophecy Surgical Planning for the Incompass Total Ankle System and the introduction of Hoffmann LRF smartHEX at the 2026 American Orthopedic Foot & Ankle Society (AOFAS) Annual Meeting. The new additions are designed to advance patient-specific surgical planning, implant flexibility and connected care across ankle replacement and limb reconstruction procedures. Management highlighted that strong customer adoption and positive feedback for Prophecy have encouraged Stryker to expand the platform to the
- Published
- 17 Sep 2026 15:00
- News subject
- Earnings
- Why this score
- Business expansion
- Company focus
- Shared story ยท 78%
- How it is used
- Direct company coverage
- Story strength
- Medium ยท 50/100
- 30-day weight
- 45% of the score ยท 3.9d old
- Duplicates
- 2 consolidated
Stryker (SYK) Stock Still Looks Cheap On Its 24% Slide
Stryker has seen its share price slide sharply over the past year, and the question now is whether the current valuation still lines up with the cash the business is expected to generate. For investors watching the stock after recent headlines, the focus has shifted from past returns to whether today's price fairly reflects those underlying cash flows. The stock has fallen 24.5% over the past year, which puts the spotlight on whether that move has brought the valuation closer to what its future cash flows can support. Ongoing manufacturing issues in the peripheral vascular business and the rel
- Published
- 15 Sep 2026 15:17
- News subject
- Regulatory and legal
- Why this score
- Negative market reaction
- Company focus
- Shared story ยท 78%
- How it is used
- Shown as company news ยท not used in the score
- Story strength
- Not directional
- 30-day weight
- None ยท 5.9d old
- Duplicates
- 1 consolidated
Why Pay More For Stryker When BSX Stock Is On Sale?
- Published
- 14 Sep 2026 18:16
- News subject
- Market update
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company ยท 100%
- How it is used
- Shown as company news ยท not used in the score
- Story strength
- Not directional
- 30-day weight
- None ยท 6.8d old
- Duplicates
- 1 consolidated
Bernstein Adjusts Price Target on Stryker to $385 From $420, Keeps Outperform Rating
- Published
- 14 Sep 2026 11:47
- News subject
- Analyst action
- Why this score
- Positive financial language
- Company focus
- Main company ยท 100%
- How it is used
- Direct company coverage
- Story strength
- Low ยท 34/100
- 30-day weight
- 11.4% of the score ยท 7.1d old
- Duplicates
- 1 consolidated
Stryker stock falls on slower peripheral vascular, hip sales
- Published
- 10 Sep 2026 12:06
- News subject
- Market update
- Why this score
- Negative market reaction
- Company focus
- Main company ยท 100%
- How it is used
- Direct company coverage
- Story strength
- Low ยท 35/100
- 30-day weight
- 1.4% of the score ยท 11.0d old
- Duplicates
- 1 consolidated
Citigroup Adjusts Stryker Price Target to $360 From $399, Maintains Buy Rating
- Published
- 09 Sep 2026 13:45
- News subject
- Analyst action
- Why this score
- Buy Rating
- Company focus
- Main company ยท 100%
- How it is used
- Direct company coverage
- Story strength
- Medium ยท 42/100
- 30-day weight
- 5.7% of the score ยท 12.0d old
- Duplicates
- 1 consolidated
Pulmera Appoints Jared Slibeck Chief Commercial Officer
Twenty-year industry veteran in surgical navigation and enabling technology joins Pulmera to spearhead commercial adoption of its CBeamโข 3D Imaging Platform, the first C-Arm Native 3D imaging system. 20-Year Stryker Veteran Jared Slibeck Joins Pulmera as Chief Commercial OfficerJared Slibeck has been named Chief Commercial Officer for Pulmera, effective September 1, 2026. Slibeck will lead the company's commercial strategy and market development as the company brings the CBeamโข 3D Imaging Platform into hospitals and surgery centers across the country. Slibeck joins Pulmera after more than twen
- Published
- 09 Sep 2026 12:58
- News subject
- Regulatory and legal
- Why this score
- The headline reports news without a clear direction
- Company focus
- Company discussed ยท 86%
- How it is used
- Shown as company news ยท not used in the score
- Story strength
- Not directional
- 30-day weight
- None ยท 12.0d old
- Duplicates
- 1 consolidated
Supply chain woes send Stryker stock tumbling 7.7%
Investing.com -- Stryker Corp. shares dropped as much as 7.7% on Tuesday morning after company executives discussed ongoing problems in its peripheral vascular and joint replacement operations at an industry conference. The company presented at the Wells Fargo Healthcare Conference, where Chief Financial Officer Preston Wells addressed issues affecting the business. Wells explained that a manufacturing problem continues to prevent the company from maintaining full inventory supply to customers. The issue also limits the company's ability to pursue new business opportunities. The company had ex
- Published
- 08 Sep 2026 15:31
- News subject
- Earnings
- Why this score
- Negative market reaction, Large negative market reaction
- Company focus
- Shared story ยท 78%
- How it is used
- Direct company coverage
- Story strength
- Low ยท 34/100
- 30-day weight
- 16.9% of the score ยท 12.9d old
- Duplicates
- 1 consolidated
Schedule update: Stryker to participate in the 2026 Wells Fargo Healthcare Conference
Stryker Corporation Portage, Michigan, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2026 Wells Fargo Healthcare Conference on Tuesday, September 8, 2026, at the Encore Boston Harbor, as previously reported. Preston Wells, Vice President, Chief Financial Officer and Nick Mead, Vice President, Investor Relations will now participate in a fireside chat session at 10:15 a.m. (Eastern time). A simultaneous live audio webcast and replay of the session can be accessed at Stryker - Events & Presentations. About Stryker Stryker is a global leader in medical technologies
- Published
- 04 Sep 2026 22:32
- News subject
- Market update
- Why this score
- The headline reports news without a clear direction
- Company focus
- Shared story ยท 78%
- How it is used
- Shown as company news ยท not used in the score
- Story strength
- Not directional
- 30-day weight
- None ยท 16.6d old
- Duplicates
- 1 consolidated
Stryker (SYK) is Buying ZuriMED. Can FiberLocker Strengthen its Shoulder Portfolio?
Stryker Corporation (NYSE:SYK) signed a definitive agreement to acquire privately held ZuriMED, which would add the commercialized FiberLocker System to its shoulder portfolio upon closing. FiberLocker is designed to reinforce rotator-cuff repairs by strengthening the connection between a surgical patch and tendon tissue. The transaction remains subject to customary closing conditions, while the purchase price and expected financial contribution were not disclosed. The strategic logic is straightforward. Stryker Corporation (NYSE:SYK) can place FiberLocker alongside its existing sports-medicin
- Published
- 04 Sep 2026 18:36
- News subject
- Deals and strategy
- Why this score
- The headline reports news without a clear direction
- Company focus
- Shared story ยท 78%
- How it is used
- Shown as company news ยท not used in the score
- Story strength
- Not directional
- 30-day weight
- None ยท 16.8d old
- Duplicates
- 1 consolidated
Stryker Launches FDA-Cleared Apple Vision Pro Surgical App
Stryker SYK recently announced the successful completion of the first hip arthroscopy procedure using its SportSuite Vision application on Apple Vision Pro at Duke Health. The milestone follows the FDA's De Novo authorization for the application in July, making it the first surgical application approved for intraoperative use with Apple's mixed reality headset. From an investor's perspective, the development reinforces Stryker's push to strengthen its digital surgery portfolio and expand innovation across its Sports Medicine business. Although the launch is unlikely to materially affect near-t
- Published
- 03 Sep 2026 17:37
- News subject
- Deals and strategy
- Why this score
- The headline reports news without a clear direction
- Company focus
- Shared story ยท 78%
- How it is used
- Shown as company news ยท not used in the score
- Story strength
- Not directional
- 30-day weight
- None ยท 17.8d old
- Duplicates
- 1 consolidated
Stryker (SYK) Wins FDA Nod And Completes First Procedure With New Surgery Software
Stryker (NYSE:SYK) received FDA De Novo authorization for its SportSuite Vision software on Apple Vision Pro in a clinical setting. The company reported completion of the first surgical procedure using SportSuite Vision in an operating room environment. The software introduces augmented reality and spatial computing tools into surgical workflows and operating room visualization. The authorization marks a regulatory milestone for Stryker in mixed reality applications for healthcare. This move into augmented reality and spatial computing is part of a wider shift across medical technology and AI
- Published
- 01 Sep 2026 17:06
- News subject
- Regulatory and legal
- Why this score
- The headline reports news without a clear direction
- Company focus
- Shared story ยท 78%
- How it is used
- Shown as company news ยท not used in the score
- Story strength
- Not directional
- 30-day weight
- None ยท 19.8d old
- Duplicates
- 1 consolidated
Stryker to add rotator cuff repair tech with ZuriMED buy
- Published
- 01 Sep 2026 17:02
- News subject
- Market update
- Why this score
- The headline reports news without a clear direction
- Company focus
- Main company ยท 100%
- How it is used
- Shown as company news ยท not used in the score
- Story strength
- Not directional
- 30-day weight
- None ยท 19.8d old
- Duplicates
- 1 consolidated
Stryker to Acquire ZuriMED to Expand Its Shoulder Care Portfolio
Stryker SYK recently announced a definitive agreement to acquire ZuriMED, developer of the FiberLocker System, a commercialized technology designed for rotator cuff augmentation with increased biomechanical strength. The acquisition is aimed at strengthening Stryker's shoulder portfolio and expanding its ability to support specialists across the continuum of shoulder care. Per Stryker management, ZuriMED's technology addresses an important unmet need for shoulder care. The addition of the FiberLocker System is expected to complement Stryker's existing offerings while reinforcing its focus on a
- Published
- 01 Sep 2026 14:10
- News subject
- Deals and strategy
- Why this score
- The headline reports news without a clear direction
- Company focus
- Shared story ยท 78%
- How it is used
- Shown as company news ยท not used in the score
- Story strength
- Not directional
- 30-day weight
- None ยท 20.0d old
- Duplicates
- 1 consolidated
Stryker introduces first of its kind FDA-authorized surgical application for Apple Vision Pro with hip arthroscopy case at nationally recognized academic medical center
SportSuite Vision brings spatial computing into the operating room, providing surgeons access to critical clinical information Stryker announced the successful completion of the first surgical procedure, a hip arthroscopy, using SportSuite Vision on Apple Vision Pro at a leading academic medical center. Stryker received FDA De Novo authorization for the first surgical application for intraoperative use with Apple Vision Pro, SportSuite Vision. SportSuite Vision brings arthroscopic video, HipCheck, HipMap and CT imaging into a customizable spatial computing environment, helping surgeons access
- Published
- 01 Sep 2026 13:05
- News subject
- Regulatory and legal
- Why this score
- The headline reports news without a clear direction
- Company focus
- Shared story ยท 78%
- How it is used
- Shown as company news ยท not used in the score
- Story strength
- Not directional
- 30-day weight
- None ยท 20.0d old
- Duplicates
- 1 consolidated
Stryker (SYK) Stock Looks Like A Bargain Near Fair Value
Stryker stock has delivered a modest total return over the past five years, while the current intrinsic value estimate from a Discounted Cash Flow (DCF) framework suggests the shares trade at a discount to that internal calculation. At the same time, market based valuation multiples point to pricing that is broadly in line with peers, which leaves investors weighing two different valuation signals. Stryker has returned about 23.3% over the past five years, which points to a measured long term outcome rather than a runaway winner or a clear disappointment. The company's ability to grow cash flo
- Published
- 31 Aug 2026 23:06
- News subject
- Earnings
- Why this score
- The headline reports news without a clear direction
- Company focus
- Shared story ยท 78%
- How it is used
- Shown as company news ยท not used in the score
- Story strength
- Not directional
- 30-day weight
- None ยท 20.6d old
- Duplicates
- 1 consolidated
Stryker signs definitive agreement to acquire ZuriMED to enhance its shoulder offering
Stryker Corporation Portage, Mich., USA, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Stryker has signed a definitive agreement to acquire ZuriMED, developer of the FiberLocker System, a commercialized technology that provides a novel approach for rotator cuff augmentation designed for increased biomechanical strength. The acquisition strengthens Stryker's shoulder portfolio, enhancing its ability to support specialists across the continuum of care. The FiberLocker System is a soft tissue augmentation technology designed to reduce the occurrence of a key clinical failure mode in rotator cuff repair, one
- Published
- 31 Aug 2026 20:05
- News subject
- Deals and strategy
- Why this score
- The headline reports news without a clear direction
- Company focus
- Shared story ยท 78%
- How it is used
- Shown as company news ยท not used in the score
- Story strength
- Not directional
- 30-day weight
- None ยท 20.7d old
- Duplicates
- 1 consolidated
Stryker to participate in the 2026 Wells Fargo Healthcare Conference
Stryker Corporation Portage, Michigan, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2026 Wells Fargo Healthcare Conference on Tuesday, September 8, 2026, at the Encore Boston Harbor. Preston Wells, Vice President, Chief Financial Officer and Nick Mead, Vice President, Investor Relations will also participate in a fireside chat session at 2:15 p.m. (Eastern time). A simultaneous live audio webcast and replay of the session can be accessed at Stryker - Events & Presentations. About Stryker Stryker is a global leader in medical technologies and, together with our c
- Published
- 27 Aug 2026 19:00
- News subject
- Market update
- Why this score
- The headline reports news without a clear direction
- Company focus
- Shared story ยท 78%
- How it is used
- Shown as company news ยท not used in the score
- Story strength
- Not directional
- 30-day weight
- None ยท 24.8d old
- Duplicates
- 1 consolidated
Earlier company news
S1YK34 news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Stryker showcases Foot & Ankle innovation at AOFAS 2026 with Prophecyยฎ Surgical Planning for Incompassโข and Hoffmannยฎ LRF smartHEXโข
New additions advance surgical planning, implant flexibility and connected care across Stryker's Foot & Ankle portfolio Stryker is launching Prophecyยฎ Surgical Planning for the Incompassโข Total Ankle System and introducing HoffmannยฎLRF smartHEXโข at the 2026 American Orthopaedic Foot & Ankle Society Annual Meeting in Seattle. Prophecyยฎ Surgical Planning, which has supported patient-specific planning for more than 100,000 ankle cases over 14 years, is now available with the Incompassโข Total Ankle System, giving surgeons access to 3D visualization and both resect-through and pin-through fixation
- Published
- 16 Sep 2026 14:06
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
US$100 Million Defense Contract Win Might Change The Case For Investing In Stryker (SYK)
Stryker's sales unit in Michigan previously secured a US$100.00 million contract modification from the U.S. Defense Logistics Agency, underscoring its role as a key supplier to government healthcare and logistics systems. This award highlights the importance of stable government contracting as a complement to Stryker's hospital and surgical product revenue mix. We'll now examine how this sizable Defense Logistics Agency contract influences Stryker's investment narrative, particularly its government-linked revenue visibility. Rare earth metals are the new gold rush. Find out which 28 stocks are
- Published
- 21 Aug 2026 17:11
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Here's Why You Should Hold Stryker Stock in Your Portfolio for Now
Stryker SYK entered 2026 facing an unexpected cyber disruption, yet underlying demand, robotics adoption and international momentum remained strong. While a robust capital pipeline and active acquisition strategy support long-term growth, execution risks tied to recovery efforts, margin pressures and expanding exposure to new markets could shape the company's performance over the coming quarters. This Zacks Rank #3 (Hold) company's shares have lost 6.7% so far this year compared with the industry's 15.2% decline. The S&P 500 Index has appreciated 11.2% in the same time frame. Stryker is a glob
- Published
- 21 Aug 2026 16:12
- Catalyst
- Macro sensitivity
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Stryker (SYK) Wins $100 Million Contract, Is It Still Below Fair Value?
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Stryker (SYK) is back in focus after its Stryker Sales unit secured a $100 million contract modification from the US Defense Logistics Agency, a development that coincided with a 2.7% share price move. See our latest analysis for Stryker. For context, Stryker's share price has been volatile around recent news, with a 4.17% 1 month share price return and a 5.88% decline year to date, while the 1 year total shareholder return is down 13.98%, the 3 year total shareholder return
- Published
- 21 Aug 2026 12:11
- Catalyst
- Deals and strategy
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?
Doctor scientist looking at test tube solution by MIND AND I via Adobe Stock Valued at a market cap of $127.1 billion, Stryker Corporation (SYK) is a global medical technology company that develops and sells a broad range of products designed to improve surgical procedures and patient outcomes. The Michigan-based company's portfolio spans MedSurg and Neurotechnology, including surgical equipment, endoscopy systems, patient-handling solutions, emergency-care products, neurovascular devices, and neurosurgical technologies, as well as Orthopaedics, covering joint replacement implants, trauma and
- Published
- 20 Aug 2026 12:20
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Why Stryker (SYK) Stock Is Trading Up Today
Why Stryker (SYK) Stock Is Trading Up Today What Happened? Shares of medical technology company Stryker (NYSE:SYK) jumped 2.7% in the afternoon session after its Stryker Sales unit in Michigan won a $100 million contract modification from the US Defense Logistics Agency. The U.S. Department of Defense announced the award, as reported by MarketScreener. This development likely boosted investor confidence in the company's revenue stream from government contracts. The shares closed the day at $340.05, up 2.6% from the previous close. Is now the time to buy Stryker? Access our full analysis report
- Published
- 19 Aug 2026 23:54
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
What Does Stryker (SYK) Q1 Growth Mean If Costs Are Still Pressuring Earnings?
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Stryker (NYSE:SYK) reported strong first quarter growth, supported by underlying demand and a recovery from a prior cyber incident. The company highlighted organic growth across its main divisions that was driven by customer volume rather than acquisitions. A wide gap between reported and adjusted earnings raised questions about ongoing costs that are weighing on profitability. For readers interested in other income focused healthcare ideas, the next logical step is to explore 11
- Published
- 14 Aug 2026 20:08
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Can Stryker (SYK) Still Look Undervalued After Backlog Recovery?
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Stryker stock has delivered a 35.9% gain over the past five years, yet current checks suggest it is not an obvious bargain, even as an Intrinsic Value estimate using a Discounted Cash Flow (DCF) framework points to the shares trading below that intrinsic value by 19.8%. Stryker's 35.9% return over five years indicates the stock has rewarded long term holders. New investors now need to weigh valuation more carefully than during earlier stages of the move. Strong demand for Str
- Published
- 14 Aug 2026 04:16
- Catalyst
- Balance sheet
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Can Stryker's Q2 Recovery and Guidance Support a Stronger Second Half?
Stryker Corporation SYK entered the second half of 2026 with momentum restored after the March cybersecurity disruption. Second-quarter sales, earnings and margins improved as production recovered, while management narrowed its full-year outlook. The next test is execution. Stryker must keep normalizing production, convert elevated backlog into shipments and support a broad product launch cycle. Those factors will determine whether the stronger second half embedded in management's expectations materializes. Stryker's Q2 Recovery Rebuilt Momentum Stryker reported second-quarter net sales of $6.
- Published
- 13 Aug 2026 18:49
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Stryker Up 13.6% in 3 Months as Recovery Gains Strength, What's Next?
Stryker Corporation SYK shares have risen 13.6% in the past three months, outpacing the Zacks Medical sector's 12.9% gain and the S&P 500's 1.7% advance. The move has coincided with a sharper operating recovery after a difficult first quarter. The investor question is whether improving sales, margins and production can keep supporting the stock, or whether execution demands and a richer relative valuation now make the next leg higher harder to achieve.Zacks Investment Research Image Source: Zacks Investment Research Why Stryker's Three-Month Rally Has Support Stryker's second-quarter results g
- Published
- 13 Aug 2026 18:49
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Wolfe Research downgrades Stryker, upgrades Abbott in med-tech shuffle
Investing.com -- Wolfe Research made two rating changes across large-cap medical devices, downgrading Stryker while upgrading Abbott Laboratories on Thursday. Analyst Mike Polark cut Stryker to Peer Perform, citing a demanding second-half setup following the company's March cyber disruption. He said the June quarter "wasn't a huge catch up thus year not yet de-risked," leaving "a higher-than-normal burden on 2H to deliver." As a result, Wolfe sees the near-term skew to estimates "leans negative," with growth "more likely to slow to 8% vs speed up to 10% in 2027." The firm flagged that Stryker'
- Published
- 13 Aug 2026 13:37
- Catalyst
- Analyst action
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Strykerโs (SYK) Comeback Quarter Looks Great, But At What Cost?
Stryker (NYSE:SYK) turned in one of its stronger quarters in recent memory on July 30, with sales climbing 9.4% to $6.6 billion and reported EPS jumping 44.1% to $3.30. The numbers arrive as the company works its way back from a cyber incident that had rattled its business, and CEO Kevin Lobo pointed to that recovery as proof of the company's resilience. But a closer look at how those earnings were adjusted tells a more complicated story about what is really driving the bottom line.Stryker's (SYK) Comeback Quarter Looks Great, But At What Cost? Bull Case: Growth That Touched Every Corner Of Th
- Published
- 11 Aug 2026 22:23
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Projeรงรตes de Resultados: Stryker Corp (SYK) โ LPA e Crescimento de Receita
- Published
- 7 Aug 2026 10:56
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Stryker declares an $0.88 per share quarterly dividend
Stryker Corporation Portage, Michigan, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable October 30, 2026, to shareholders of record at the close of business on September 30, 2026, representing an increase of 4.8% versus the prior year and unchanged from the previous quarter. About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopa
- Published
- 5 Aug 2026 14:34
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Earnings call transcript: Stryker beats Q2 2026 estimates but shares fall
- Published
- 3 Aug 2026 15:40
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Solventum (SOLV) Appoints Neil Zieselman As New Chief Accounting Officer
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Solventum (NYSE:SOLV) has appointed Neil Zieselman as Senior Vice President, Controller, and Chief Accounting Officer. He will succeed current Controller and Chief Accounting Officer Mary Wilcox following her retirement. Zieselman brings experience from Surgery Partners Inc., Stryker Corporation, Covanta Holding Corporation, Cendant Corporation, and Avaya Inc., and is a licensed CPA. Solventum enters this leadership change w
- Published
- 2 Aug 2026 15:08
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Is Stryker (SYK) Undervalued As Earnings Trigger A Fresh Valuation Question?
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Stryker (SYK) is back in focus after its second quarter 2026 earnings, reporting sales of US$6.59b and net income of US$1.28b, alongside a sharp market reaction to the release. See our latest analysis for Stryker. The 1 day share price return of Stryker fell 6.42% on the earnings release, which pulled the year to date share price return down 6.46%, while the 5 year total shareholder return of 30.66% still reflects longer term gains. If Stryker's move has y
- Published
- 2 Aug 2026 02:11
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
How Strong Q2 Earnings, Raised Guidance and Cyber Recovery Will Impact Stryker (SYK) Investors
Stryker Corporation's recently reported Q2 2026 results showed sales rising to US$6,589 million and net income to US$1,276 million, with both basic and diluted EPS from continuing operations increasing compared with the prior year period. Management also highlighted 9% organic sales growth, recovery progress after a March cyberattack that disrupted operations, and a slight increase to full-year adjusted EPS guidance while planning to resume share repurchases. We will now examine how this combination of strong earnings, raised guidance, and post-cyberattack recovery shapes Stryker's broader inv
- Published
- 1 Aug 2026 17:12
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
SYK Q2 Deep Dive: Supply Chain Disruptions Weigh on Growth Outlook Despite Margin Expansion
SYK Q2 Deep Dive: Supply Chain Disruptions Weigh on Growth Outlook Despite Margin Expansion Medical technology company Stryker (NYSE:SYK) met Wall Street's revenue expectations in Q2 CY2026, with sales up 9.4% year on year to $6.59 billion. Its non-GAAP profit of $3.69 per share was 5.8% above analysts' consensus estimates. Is now the time to buy SYK? Find out in our full research report (it's free). Stryker (SYK) Q2 CY2026 Highlights: Revenue: $6.59 billion vs analyst estimates of $6.57 billion (9.4% year-on-year growth, in line) Adjusted EPS: $3.69 vs analyst estimates of $3.49 (5.8% beat) M
- Published
- 1 Aug 2026 04:31
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Stryker stock breaks $314.99 support after quarterly revenue misses consensus forecast
- Published
- 31 Jul 2026 20:37
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Why Stryker (SYK) Shares Are Plunging Today
Why Stryker (SYK) Shares Are Plunging Today What Happened? Shares of medical technology company Stryker (NYSE:SYK) fell 7.3% in the morning session after the company reported second-quarter results that showed revenue that only met Wall Street's expectations and organic sales growth that missed forecasts. While the company reported a solid 9.4% year-on-year increase in revenue to $6.59 billion, investors were likely expecting a stronger performance. The 9% organic revenue growth, a key measure of core business health that strips out acquisitions and currency effects, fell short of expectations
- Published
- 31 Jul 2026 16:23
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Stryker nets $6.6bn revenue in Q2; highlights resilience following cyberattack
Stryker has reported Q2 revenues of $6.6bn, denoting a 9.4% rise year-over-year (YoY), with the company's CEO lauding its "significant progress" in recovering since its global operations were disrupted by an cyberattack in March. Following the results, Stryker is tweaking its 2026 outlook at the low end, with earnings now projected to land in the $14.95 to $15.10 per share range, up from $14.90 to $15.10 previously. Stryker's orthopaedic segment revenues totalled almost $3bn, representing a YoY uptick of 9.2%. Meanwhile the majority of proceeds for the quarter came from the company's medsurg a
- Published
- 31 Jul 2026 12:23
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Stryker Corp (SYK) (Q2 2026) Earnings Call Highlights: Strong 9% Organic Growth and Raised ...
This article first appeared on GuruFocus. Organic Sales Growth: 9% for Q2 2026, against a double-digit comparable in Q2 2025. Adjusted EPS: $3.69, up 17.9% year-over-year. Adjusted Gross Margin: 66%, 60 basis points favorable to Q2 2025. Adjusted Operating Margin: 27.4% of sales, 170 basis points favorable to Q2 2025. Adjusted Effective Tax Rate: 16.5% for Q2 2026. Cash and Marketable Securities: Approximately $3.5 billion at end of Q2. Year-to-Date Cash from Operations: $1.8 billion. MedSurg and Neurotechnology Organic Sales Growth: 9.2% (US: 8.9%, International: 10.5%). Orthopaedics Organic
- Published
- 31 Jul 2026 06:04
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Stryker (SYK): Company Profile, Stock Price, News, Rankings
- Published
- 31 Jul 2026 03:54
- Catalyst
- Legacy snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Stryker expects 8.3%-9.3% organic sales growth and $14.95-$15.10 adjusted EPS in 2026 as it resumes share repurchases
Earnings Call Insights: Stryker (SYK) Q2 2026 MANAGEMENT VIEW * CEO Kevin Lobo said, "Our second quarter results demonstrated the strength of our broad product portfolio and resiliency of our teams," and added, "Our recovery from the cybersecurity incident continued as we ramped overall production to meet ongoing demand and support patient care." * Lobo highlighted the operational setback in Peripheral Vascular and the expected timing of normalization: "the supply disruption resulted in a meaningful back order situation with lost sales in the quarter. We have addressed the issue and back order
- Published
- 31 Jul 2026 02:36
- Catalyst
- Macro sensitivity
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Stryker (SYK) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
For the quarter ended June 2026, Stryker (SYK) reported revenue of $6.59 billion, up 9.4% over the same period last year. EPS came in at $3.69, compared to $3.13 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $6.56 billion, representing a surprise of +0.48%. The company delivered an EPS surprise of +6.65%, with the consensus EPS estimate being $3.46. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate pictur
- Published
- 30 Jul 2026 23:00
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Stryker (NYSE:SYK) Posts Q2 CY2026 Sales In Line With Estimates But Stock Drops
Stryker (NYSE:SYK) Posts Q2 CY2026 Sales In Line With Estimates But Stock Drops Medical technology company Stryker (NYSE:SYK) met Wall Street's revenue expectations in Q2 CY2026, with sales up 9.4% year on year to $6.59 billion. Its non-GAAP profit of $3.69 per share was 5.8% above analysts' consensus estimates. Is now the time to buy Stryker? Find out in our full research report. Stryker (SYK) Q2 CY2026 Highlights: Revenue: $6.59 billion vs analyst estimates of $6.57 billion (9.4% year-on-year growth, in line) Adjusted EPS: $3.69 vs analyst estimates of $3.49 (5.8% beat) Management slightly r
- Published
- 30 Jul 2026 21:30
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Stryker reports second quarter 2026 operating results
Portage, Michigan, July 30, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the second quarter of 2026: Second Quarter Results Reported net sales increased9.4% to $6.6 billionOrganic net sales increased9.0%Reported operating income margin of 25.2%Adjusted operating income margin(1)increased170 bps to27.4%Reported EPS increased44.1% to $3.30Adjusted EPS(1)increased17.9% to $3.69 Second Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology 9.7 % 0.5 % 9.2 % โ % 9.2 %Orthopae
- Published
- 30 Jul 2026 21:05
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 2 consolidated
Stryker (SYK) Launches Mako RPS To Bring Robotic Knee Surgery To More Surgeons
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Stryker has introduced Mako RPS, a robotic handheld system for total knee replacement, expanding its Mako robotics portfolio. The launch extends robotic assistance to a wider range of orthopaedic procedures and care settings. The development highlights Stryker's focus on robotic-assisted surgery and surgeon flexibility in knee replacement. Stryker, traded as NYSE:SYK, is drawing attention with the launch of Mako RPS alongside a share price of $336.74. The stock is up 5.5% ove
- Published
- 28 Jul 2026 15:07
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
PAHC vs. SYK: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Stryker (SYK). But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identif
- Published
- 27 Jul 2026 16:40
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Provider matches checked
Provider mentions not used in the score
A news provider linked these stories to S1YK34, but the headline and available text are not mainly about Stryker Corporation. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of S1YK34 sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.